Case Study · Multiple Sclerosis
60 sites needed.
76 delivered, 50% in under 7 days.
How AcceleTrial helped a large global pharma sponsor exceed site targets for a competitive Multiple Sclerosis trial on compressed timelines.
The Challenge
A competitive indication.
Compressed timelines. High stakes.
The sponsor needed a large, qualified site network in Multiple Sclerosis, one of the most competitive therapeutic areas in clinical development, without sacrificing timeline integrity.
The sponsor needed 60 interested clinical sites (40 to activate, 20 to hold as backup) in Multiple Sclerosis, a therapeutic area with intense competition for qualified investigators and patient populations.
The team needed to communicate with a large volume of clinical sites and execute Confidentiality Disclosure Agreements and Feasibility Questionnaires on an accelerated schedule with no margin for delay.
Sites needed to be activated efficiently and quickly to meet or exceed the sponsor's targeted timelines. Every delay in activation created downstream risk for the overall trial schedule.
The Solution
AcceleTrial identified
76 pre-qualified sites
Using AcceleTrial, LINEA System identified 76 pre-qualified clinical sites with specific MS expertise and verified patient access. With the platform's workflow automation, 50% of sites completed CDAs and feasibility questionnaires in under 7 days.
Half of all sites completed both the Confidentiality Disclosure Agreement and Feasibility Questionnaire in under 7 days. The rapid FQ turnaround was the key driver that allowed the team to accelerate site selection and stay ahead of the sponsor's schedule.
Outcomes
Targets exceeded.
Timeline compressed.
76 pre-qualified MS sites delivered against a sponsor target of 60, providing both the full activation cohort and a strong backup pool.
Half of all sites completed both the CDA and Feasibility Questionnaire within 7 days, materially compressing the site selection cycle.
The sponsor selected 40 sites from LINEA's delivery to date, meeting the activation target of 40.
LINEA identified 27% more sites than the sponsor requested, providing strategic backup capacity in a highly competitive therapeutic area.
Get the Full Story
Download the case study
or see AcceleTrial live
Get the one-page PDF summary or request a personalized demo using your protocol and therapeutic area.